WO2012030309A3 - Formulation of comprising tiotropium and a calcium channel blocker - Google Patents
Formulation of comprising tiotropium and a calcium channel blocker Download PDFInfo
- Publication number
- WO2012030309A3 WO2012030309A3 PCT/TR2011/000199 TR2011000199W WO2012030309A3 WO 2012030309 A3 WO2012030309 A3 WO 2012030309A3 TR 2011000199 W TR2011000199 W TR 2011000199W WO 2012030309 A3 WO2012030309 A3 WO 2012030309A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tiotropium
- calcium channel
- channel blocker
- formulation
- copd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Abstract
The present invention relates to a dry powder formulation comprising at least one calcium channel blocker and tiotropium developed in order to be used in respiratory tract diseases such as asthma and COPD.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11767092.7A EP2611447A2 (en) | 2010-09-01 | 2011-08-24 | Formulation of comprising tiotropium and a calcium channel blocker |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2010/07251 | 2010-09-01 | ||
TR2010/07251A TR201007251A2 (en) | 2010-09-01 | 2010-09-01 | Calcium channel blocker formulation. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012030309A2 WO2012030309A2 (en) | 2012-03-08 |
WO2012030309A3 true WO2012030309A3 (en) | 2012-08-09 |
Family
ID=44764205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000199 WO2012030309A2 (en) | 2010-09-01 | 2011-08-24 | Formulation of calcium channel blocker |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2611447A2 (en) |
TR (1) | TR201007251A2 (en) |
WO (1) | WO2012030309A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2543470T3 (en) * | 2009-09-30 | 2015-08-19 | Microdose Therapeutx, Inc. | Methods and compositions for the treatment of Raynaud's phenomenon |
JP6092015B2 (en) * | 2013-06-19 | 2017-03-08 | 日本碍子株式会社 | Method for producing single crystal |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR890004691B1 (en) * | 1985-07-02 | 1989-11-25 | 키 파마슈티칼스, 인코포레이티드 | Composition for the treatment of chronic obstructive pulmonary disease |
US20020106332A1 (en) * | 2000-10-12 | 2002-08-08 | Michael Walz | Process for preparing powder formulations |
US20020110529A1 (en) * | 2000-10-12 | 2002-08-15 | Karoline Bechtold-Peters | Inhalable powder containing tiotropium |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
WO2003088944A1 (en) * | 2002-04-13 | 2003-10-30 | Glaxo Group Limited | Dry powder inhalant composition |
WO2008152398A2 (en) * | 2007-06-14 | 2008-12-18 | Cipla Limited | Formulations for inhalation |
US20090088408A1 (en) * | 2001-06-23 | 2009-04-02 | Meade Christopher J M | Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1680324A (en) | 2000-05-30 | 2005-10-12 | 奥索-麦克尼尔药品公司 | Dihydropyridine soft drugs, and related compositions and methods |
-
2010
- 2010-09-01 TR TR2010/07251A patent/TR201007251A2/en unknown
-
2011
- 2011-08-24 EP EP11767092.7A patent/EP2611447A2/en not_active Withdrawn
- 2011-08-24 WO PCT/TR2011/000199 patent/WO2012030309A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR890004691B1 (en) * | 1985-07-02 | 1989-11-25 | 키 파마슈티칼스, 인코포레이티드 | Composition for the treatment of chronic obstructive pulmonary disease |
US20020106332A1 (en) * | 2000-10-12 | 2002-08-08 | Michael Walz | Process for preparing powder formulations |
US20020110529A1 (en) * | 2000-10-12 | 2002-08-15 | Karoline Bechtold-Peters | Inhalable powder containing tiotropium |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
US20090088408A1 (en) * | 2001-06-23 | 2009-04-02 | Meade Christopher J M | Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics |
WO2003088944A1 (en) * | 2002-04-13 | 2003-10-30 | Glaxo Group Limited | Dry powder inhalant composition |
WO2008152398A2 (en) * | 2007-06-14 | 2008-12-18 | Cipla Limited | Formulations for inhalation |
Also Published As
Publication number | Publication date |
---|---|
EP2611447A2 (en) | 2013-07-10 |
TR201007251A2 (en) | 2012-03-21 |
WO2012030309A2 (en) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252122B (en) | Process, tube and device for the preparation of wound healant composition | |
HK1222128A1 (en) | Methods and compositions for the preparation of aerosols | |
WO2011152804A3 (en) | Process for dry powder formulations | |
HK1185796A1 (en) | Compositions comprising a near terminal-branched compound and methods of making the same | |
EP2569425A4 (en) | Endoribonuclease compositions and methods of use thereof | |
IL226448A (en) | Immunogenic composition comprising an m72 related antigen and uses thereof in the manufacture of a medicament | |
WO2012016889A3 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
WO2011131943A3 (en) | Pharmaceutical compositions | |
EP3013348A4 (en) | A medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same | |
WO2010094731A3 (en) | Pharmaceutical composition for inhalation | |
ZA201209739B (en) | Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof | |
IL222723A0 (en) | Respiratory syncytial virus antigenic compositions and methods | |
EP2370068A4 (en) | Methods and compositions for delivery of medicaments to the lungs | |
SG10201502583VA (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
HK1169334A1 (en) | Inhaled combination product for asthma | |
WO2012030309A3 (en) | Formulation of comprising tiotropium and a calcium channel blocker | |
WO2012030308A3 (en) | Formulation comprising cellobiose | |
IL226174A0 (en) | Propellant compositions and methods of making and using the same | |
EP2866792A4 (en) | Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture | |
ZA201105443B (en) | Novel saponin compounds,methods of preparation thereof,use thereof and pharmaceutical compositions | |
EP2677868A4 (en) | Pharmaceutical compositions of maraviroc and process for the preparation thereof | |
IL217137A0 (en) | Medicinal and herbal composition and uses thereof | |
WO2013109213A3 (en) | Pharmaceutical formulations comprising tiotropium | |
EP2590621A4 (en) | Antiperspirant compositions and methods for manufacturing the same | |
WO2014062143A3 (en) | Combinations of glycopyrrolate and an anticholinergic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11767092 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011767092 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |